Texas MPN Workshop 2021 | An update on emerging therapies for the treatment of polycythemia vera
Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses the current treatment paradigm used for polycythemia vera and highlights emerging treatments and their impact on the therapeutic landscape in the future. One of the most promising treatments discussed is ropeginterferon alfa-2b. Dr Kuykendall briefly speaks about the PROUD-PV study (NCT01949805) which has suggested its superiority to hydroxyurea, the current standard treatment available. Dr Kuykendall additionally speaks about another promising agent called rusfertide, a hepcidin-mimetic which has been shown to reduce the need for phlebotomy. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
Disclosures
Andrew Kuykendall, MD, has received research fees from Protagonist, Sierra and Prelude; has participated in steering committees for Constellation and Protagonist; has participated in consultancy for Protagonist; has received honoraria from and/or participated in advisory boards with Pharmaessentia, BMS/Celgene, Incyte, Novartis, Abbvie and Blueprint; and has participated in speakers’ bureau for Novartis, Blueprint and BMS/Celgene.
